

## Technology Appraisal Committee Meeting (Committee B)

**Minutes:** **Confirmed**

**Date and Time:** Wednesday 3 February from 10am to 6pm

**Venue:**  
**Prospero House**  
**241 Borough High Street**  
**London**  
**SE1 1GA**

<b>Present:</b>	1. Dr Amanda Adler (Chair) 2. Dr Sanjeev Patel (Vice-Chair) 3. Dr Ray Armstrong 4. Dr Jeff Aronson 5. Professor John Cairns 6. Dr Rebecca Kearney 7. Dr Sanjay Kinra 8. Dr Miriam McCarthy 9. Professor Ruairidh Milne 10. Mr Christopher O'Regan 11. Professor Stephen Palmer 12. Professor John Pounsford 13. Dr Danielle Preedy 14. Dr Nigel De-Kare Silver 15. Dr Marta Soares 16. Professor Ken Stein 17. Dr Nicky Welton 18. Mr Nigel Westwood	Present for all notes Present for all notes
-----------------	---	---

### **In attendance:**

Dr Melinda Goodall	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Dr Elisabeth George	Associate Director, National Institute for Health and Care Excellence	Present for notes 21 to 32
Mr Jeremy Powell	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Ms Marcia Miller	Administrator, National Institute for Health and Care Excellence	Present for all notes

Mr Richard Diaz	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 20
Ms Raisa Sidhu	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 1 to 20
Dr Rosie Lovett	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 21 to 32
Dr Miriam Brazzelli	Senior Research Fellow, Aberdeen HTA Group	Present for notes 1 to 18
Dr Ewen Cummins	Health Economist, Aberdeen HTA Group	Present for notes 1 to 18
Professor Craig Ramsay	HCA Programme Director and Senior Statistician, Aberdeen HTA Group	Present for notes 1 to 18
Dr George Follows	Consultant Haematologist, Cambridge University Hospitals NHS Foundation Trust, nominated by the UK CLL Forum	Present for notes 7 to 16
Professor Peter Hillmen	Professor of experimental haematology, University of Leeds, nominated by Janssen	Present for notes 7 to 16
Ms Molly Fletcher	Patient expert, nominated by the CLL Support Association	Present for notes 7 to 16
Mr Nick York	Patient expert and Trustee of the CLL Support Association, nominated by the CLL Support Association	Present for notes 7 to 16
Dr Bram Ramaekers	Health Economist, Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical	Present for notes 21 to 31

**Non-public observers:**

Professor Nicky Britten	Professor of Applied Health Care Research, NIHR PenCLAHRC Theme Lead for Person	Present for notes 1 to 16
-------------------------	--	---------------------------

Ms Linda Grainger	Centred Care, University of Exeter Medical School	
Ms Chloe Kastoryano	Medical editor, NICE	Present for all notes
Ms Pilar Pinilla-Dominguez	PIP Advisor, NICE	Present for all notes
	Technical Advisor, NICE	Present for notes 1 to 29
	Scientific Advice	

## Notes

### Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of ibrutinib for treating chronic lymphocytic leukaemia [ID749] and abiraterone acetate for the treatment of metastatic hormone relapsed prostate cancer not previously treated with chemotherapy [ID503].
2. The Chair welcomed Mr Nigel Westwood to his first meeting as a member of the Appraisal Committee.
3. The Chair welcomed Dr Sanjeev Patel to his first meeting as Vice-Chair of the Committee.
4. The Chair informed the Committee of the non-public observers at this meeting: Professor Nicky Britten, Ms Linda Grainger, Ms Chloe Kastoryano and Ms Pilar Pinilla-Dominguez.
5. Apologies were received from Mr Mark Chapman, Dr Neil Iosson, Ms Anne Joshua and Mr Alun Roebuck.

### Any other Business

6. The Committee were given an update on issues and timings relating to other appraisals.

### Notes from the last meeting

7. The minutes of the 6 January Committee meeting were approved.

### Appraisal of ibrutinib for treating chronic lymphocytic leukaemia [ID749]

#### Part 1 – Open session

8. The Chair welcomed the invited experts: Dr Miriam Brazzelli, Dr Ewen Cummins, Professor Craig Ramsay, Dr George Follows, Professor Peter Hillmen, Ms Molly Fletcher and Mr Nick York to the meeting and they introduced themselves to the Committee.
9. The Chair welcomed company representatives from Janssen to the meeting.
10. The Chair asked all Committee members to declare any relevant interests
  - 10.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Ray Armstrong, Dr Jeff Aronson, Professor John Cairns, Dr Rebecca Kearney, Dr Sanjay Kinra, Dr Miriam

McCarthy, Professor Ruairidh Milne, Mr Christopher O'Regan, Professor Stephen Palmer, Professor John Poundsford, Dr Danielle Preedy, Dr Nigel De-Kare Silver, Dr Marta Soares, Professor Ken Stein, Dr Nicky Welton and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ibrutinib for treating chronic lymphocytic leukaemia.

11. The Chair asked all NICE Staff to declare any relevant interests.
  - 11.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ibrutinib for treating chronic lymphocytic leukaemia
12. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
  - 12.1. Dr Miriam Brazzelli, Dr Ewen Cummins, Professor Craig Ramsay and Ms Molly Fletcher declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ibrutinib for treating chronic lymphocytic leukaemia.
  - 12.2. Dr George Follows declared a personal non-specific financial interest as he has sat on advisory boards, provided consultancy and paid lectures for companies including Janssen, Gilead, Abbvie, Roche, GSK, Celgene, Mundipharma, Napp, CTi therapeutics, Takeda and local Cambridge biotech companies. He also stated that he has attended conferences in the UK and overseas as a sponsored guest of companies including Janssen and Takeda. Dr Follows also stated that he has share holdings (all less than £5,000) in a number of pharmaceutical biotechnology companies, but none which manufacture or market a drug licensed to treat CLL.
    - 12.2.1. It was agreed that these declarations would not prevent Dr Follows from participating in this section of the meeting
  - 12.3. Professor Peter Hillmen declared a personal non-specific financial interest as he has received honoraria and research support from Janssen and other pharmaceutical companies.
    - 12.3.1. It was agreed that this declaration would not prevent Professor Hillmen from participating in this section of the meeting
  - 12.4. Mr Nick York declared a non-personal non-specific financial interest as he is a trustee of the CLL Support Association which receives unrestricted educational grants from several pharmaceutical companies.
    - 12.4.1. It was agreed that this declaration would not prevent Mr York from participating in this section of the meeting

13. The Chair introduced the lead team, Dr Ray Armstrong, Professor Ken Stein and Dr Dani Preedy who gave presentations on the clinical effectiveness and cost effectiveness of ibrutinib for treating chronic lymphocytic leukaemia.
14. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
15. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
16. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

17. Discussion on confidential information continued. This information was supplied by the company.
18. The Chair then thanked the Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.
19. The Committee continued to discuss the clinical and cost effectiveness of ibrutinib for treating chronic lymphocytic leukaemia.
20. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## **Appraisal of abiraterone acetate for the treatment of metastatic hormone relapsed prostate cancer not previously treated with chemotherapy [ID503]**

### **Part 1 – Open session**

21. The Chair welcomed the invited expert: Dr Bram Ramaekers to the meeting and he introduced himself to the Committee.
22. The Chair welcomed company representatives from Janssen to the meeting.
23. The Chair asked all Committee members to declare any relevant interests
  - 23.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Ray Armstrong, Dr Jeff Aronson, Professor John Cairns, Dr Rebecca Kearney, Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Ruairidh Milne, Mr Christopher O'Regan, Professor Stephen Palmer, Professor John Pounsford, Dr Danielle Preedy, Dr Nigel De-Kare Silver, Dr Marta Soares, Professor Ken Stein, Dr Nicky Welton and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the

appraisal of abiraterone acetate for the treatment of metastatic hormone relapsed prostate cancer not previously treated with chemotherapy.

24. The Chair asked all NICE Staff to declare any relevant interests.
  - 24.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of abiraterone acetate for the treatment of metastatic hormone relapsed prostate cancer not previously treated with chemotherapy.
25. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
  - 25.1. Dr Bram Ramaekers declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of abiraterone acetate for the treatment of metastatic hormone relapsed prostate cancer not previously treated with chemotherapy.
26. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
27. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
28. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960" and all public attendees left the meeting.
29. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

30. Discussion on confidential information continued. This information was supplied by the company.
31. The Chair then thanked the Evidence Review Group representative for his attendance, participation and contribution to the appraisal and he left the meeting.
32. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## **Date, time and venue of the next meeting**

33. Wednesday 2 March 2016 at Prospero House, 241 Borough High Street, London, SE1 1GA